Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more
Alector Inc (ALEC) - Net Assets
Latest net assets as of December 2025: $30.65 Million USD
Based on the latest financial reports, Alector Inc (ALEC) has net assets worth $30.65 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($293.24 Million) and total liabilities ($262.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $30.65 Million |
| % of Total Assets | 10.45% |
| Annual Growth Rate | N/A |
| 5-Year Change | -89.81% |
| 10-Year Change | N/A |
| Growth Volatility | 36.44 |
Alector Inc - Net Assets Trend (2016–2025)
This chart illustrates how Alector Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alector Inc (2016–2025)
The table below shows the annual net assets of Alector Inc from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $30.65 Million | -75.83% |
| 2024-12-31 | $126.80 Million | -5.48% |
| 2023-12-31 | $134.16 Million | -37.44% |
| 2022-12-31 | $214.44 Million | -28.69% |
| 2021-12-31 | $300.72 Million | +12.41% |
| 2020-12-31 | $267.53 Million | +37.38% |
| 2019-12-31 | $194.74 Million | +299.95% |
| 2018-12-31 | $-97.40 Million | -87.19% |
| 2017-12-31 | $-52.03 Million | -108.91% |
| 2016-12-31 | $-24.91 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alector Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 94234900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.04% |
| Other Comprehensive Income | $166.00K | 0.54% |
| Other Components | $1.00 Billion | 3271.00% |
| Total Equity | $30.65 Million | 100.00% |
Alector Inc Competitors by Market Cap
The table below lists competitors of Alector Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tianjin Guifaxiang 18th Street Mahua Food Co Ltd
SHE:002820
|
$192.71 Million |
|
Lanner Electronics
TWO:6245
|
$192.80 Million |
|
Shifeng Cultural Development Co Ltd
SHE:002862
|
$192.82 Million |
|
Yongyue Science & Tech Co Ltd
SHG:603879
|
$192.82 Million |
|
Nanjing Inform Storage Equip
SHG:603066
|
$192.61 Million |
|
Sido Muncul PT
JK:SIDO
|
$192.60 Million |
|
Chongqing Constr Engineering
SHG:600939
|
$192.58 Million |
|
Kepler Weber S.A
SA:KEPL3
|
$192.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alector Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 126,800,000 to 30,649,000, a change of -96,151,000 (-75.8%).
- Net loss of 142,929,000 reduced equity.
- New share issuances of 19,983,000 increased equity.
- Other comprehensive income decreased equity by 95,000.
- Other factors increased equity by 26,890,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-142.93 Million | -466.34% |
| Share Issuances | $19.98 Million | +65.2% |
| Other Comprehensive Income | $-95.00K | -0.31% |
| Other Changes | $26.89 Million | +87.74% |
| Total Change | $- | -75.83% |
Book Value vs Market Value Analysis
This analysis compares Alector Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-2.93 | $2.23 | x |
| 2017-12-31 | $-1.02 | $2.23 | x |
| 2018-12-31 | $-1.42 | $2.23 | x |
| 2019-12-31 | $3.15 | $2.23 | x |
| 2020-12-31 | $3.44 | $2.23 | x |
| 2021-12-31 | $3.74 | $2.23 | x |
| 2022-12-31 | $2.60 | $2.23 | x |
| 2023-12-31 | $1.60 | $2.23 | x |
| 2024-12-31 | $1.31 | $2.23 | x |
| 2025-12-31 | $0.30 | $2.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alector Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -466.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -679.16%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 9.57x
- Recent ROE (-466.34%) is below the historical average (-84.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -3632.21% | 0.01x | 0.00x | $-12.62 Million |
| 2017 | 0.00% | -869.61% | 0.02x | 0.00x | $-27.28 Million |
| 2018 | 0.00% | -188.78% | 0.09x | 0.00x | $-42.51 Million |
| 2019 | -51.25% | -470.39% | 0.05x | 2.17x | $-119.29 Million |
| 2020 | -68.39% | -867.21% | 0.04x | 1.83x | $-209.72 Million |
| 2021 | -9.32% | -13.53% | 0.25x | 2.71x | $-58.09 Million |
| 2022 | -62.17% | -99.77% | 0.17x | 3.67x | $-154.75 Million |
| 2023 | -97.19% | -134.34% | 0.16x | 4.64x | $-143.81 Million |
| 2024 | -93.89% | -118.39% | 0.21x | 3.69x | $-131.73 Million |
| 2025 | -466.34% | -679.16% | 0.07x | 9.57x | $-145.99 Million |
Industry Comparison
This section compares Alector Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alector Inc (ALEC) | $30.65 Million | 0.00% | 8.57x | $192.67 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |